Oligoastrocytoma secondary prevention: Difference between revisions
No edit summary |
|||
| Line 8: | Line 8: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
===Follow up after treatment=== | ===Follow up after treatment=== | ||
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures | Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures for oligoastrocytoma include:<ref name="pmid20555079">{{cite journal| author=Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group| title=High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2010 | volume= 21 Suppl 5 | issue= | pages= v190-3 | pmid=20555079 | doi=10.1093/annonc/mdq187 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20555079 }} </ref> | ||
*Clinical assessment of [[neurology|neurological function]] | *Clinical assessment of [[neurology|neurological function]] | ||
*Tapering [[steroid]] usage as early as possible | *Tapering [[steroid]] usage as early as possible | ||
| Line 16: | Line 16: | ||
*MRI every 3-4 months | *MRI every 3-4 months | ||
*[[PET|Positron emission tomography]] | *[[PET|Positron emission tomography]] | ||
**To differentiate [[tumor]] recurrence from radiation-induced tumor [[necrosis]] | **To differentiate [[tumor]] recurrence from radiation-induced tumor [[necrosis]] | ||
==References== | ==References== | ||
Revision as of 14:48, 19 October 2015
|
Oligoastrocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligoastrocytoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Oligoastrocytoma secondary prevention |
|
Risk calculators and risk factors for Oligoastrocytoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strategies following oligoastrocytoma include a clinical assessment of neurological function and corticosteroid usage (Macdonald criteria), checking for signs of venous thromboembolism, regular laboratory tests, and routine imaging (MRI and Positron Emission Tomography) at scheduled intervals after treatment.[1]
Secondary Prevention
Follow up after treatment
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures for oligoastrocytoma include:[1]
- Clinical assessment of neurological function
- Tapering steroid usage as early as possible
- Checking for signs of venous thromboembolism
- Laboratory tests
- Generally not indicated, unless patient is on chemotherapy (complete blood count), steroids (glucose level), and anticonvulsants (complete blood count and liver function tests)
- MRI every 3-4 months
- Positron emission tomography
References
- ↑ 1.0 1.1 Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group (2010). "High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 21 Suppl 5: v190–3. doi:10.1093/annonc/mdq187. PMID 20555079.